Delivery Order SPE2DB22D9353-SPE2DB24FX2BG

Award Date 7/22/24
Potential Completion Date 8/12/24
Potential Value $6.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was made by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $6,848.92 firm fixed-price delivery order is for the supply of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with a completion date of June 18, 2025. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to...
The federal contract award, valued at $6,848.92, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a specialized pharmaceutical product. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $34,244.60 firm fixed-price delivery order is for the supply of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with an ultimate completion date of August 2, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999,...
This federal contract award, valued at $3,405.36, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a delivery order for the supply of XOLAIR 75 MG/0.5 ML AUTOINJECT 0.5ML, a pharmaceutical product, with a period of performance through June 2, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award was made by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $2,568.33 firm fixed-price delivery order is for the supply of XOLAIR 150 MG/ML AUTOINJECTORML, with an ultimate completion date of October 7, 2024. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows...
This federal contract award was made by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,424.46 firm fixed-price delivery order is for the supply of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with a performance period ending on June 25, 2025. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $13,697.84 firm fixed-price delivery order is for the supply of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a specialized pharmaceutical product. The contract has an ultimate completion date of April 10, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC)...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,712.23 firm fixed-price delivery order is for the supply of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with a completion date of May 14, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $25,683.40 firm fixed-price delivery order is for the supply of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a pharmaceutical product. The contract has an ultimate completion date of July 1, 2025. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $6,848.92 firm fixed-price delivery order is for the supply of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a specialized pharmaceutical product. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to...
  • SPE2DB22D9353
    Indefinite Delivery Contract
  • SPE2DB22D9353-SPE2DB24FX2BG
    Delivery Order

This federal contract award, valued at $6,848.92, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with a completion date of August 12, 2024.

DMS Pharmaceutical Group Inc. holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December 31, 2025. This single-award IDC allows the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to fulfill the recurring medical supply needs of military health facilities worldwide. The contract does not have a set-aside designation.

Generated 10/21/24, 9:21 AM